332 related articles for article (PubMed ID: 20412044)
21. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
22. BIBF 1120 for the treatment of non-small cell lung cancer.
Reck M
Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
[TBL] [Abstract][Full Text] [Related]
23. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope.
Ramalingam SS; Belani CP
Curr Opin Oncol; 2010 Mar; 22(2):79-85. PubMed ID: 20009926
[TBL] [Abstract][Full Text] [Related]
25. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
Aggarwal C; Somaiah N; Simon G
Cancer Biol Ther; 2012 Mar; 13(5):247-63. PubMed ID: 22481432
[TBL] [Abstract][Full Text] [Related]
27. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
28. Nintedanib for the treatment of non-small-cell lung cancer.
Rashdan S; Hanna N
Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
[TBL] [Abstract][Full Text] [Related]
29. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.
Stegehuis JH; de Wilt LH; de Vries EG; Groen HJ; de Jong S; Kruyt FA
Drug Resist Updat; 2010; 13(1-2):2-15. PubMed ID: 20036602
[TBL] [Abstract][Full Text] [Related]
30. Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Chatterjee S; Wieczorek C; Schöttle J; Siobal M; Hinze Y; Franz T; Florin A; Adamczak J; Heukamp LC; Neumaier B; Ullrich RT
Cancer Res; 2014 May; 74(10):2816-24. PubMed ID: 24675359
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
Ulahannan SV; Brahmer JR
Cancer Invest; 2011 May; 29(4):325-37. PubMed ID: 21469981
[TBL] [Abstract][Full Text] [Related]
32. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
Byers LA; Heymach JV
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S79-85. PubMed ID: 17382029
[TBL] [Abstract][Full Text] [Related]
33. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
Ellis PM; Al-Saleh K
Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
[TBL] [Abstract][Full Text] [Related]
34. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Wang S; Yang Z; Wang Z
Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO; Heymach JV
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
[TBL] [Abstract][Full Text] [Related]
36. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
[TBL] [Abstract][Full Text] [Related]
37. [Targeted therapies in the treatment of non-small cell lung cancer].
De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Keedy VL; Sandler AB
Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
[TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
40. Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).
Schmid-Bindert G
Target Oncol; 2013 Mar; 8(1):15-26. PubMed ID: 23371029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
